No Data
Huasheng Zhongtian Pharmaceutical-B (02563.HK) intends to hold a Board of Directors meeting on March 31 to approve the annual performance.
Gelonghui announced on March 17 that Huahao Zhongtian Pharmaceutical-B (02563.HK) will hold a Board of Directors meeting on March 31, 2025 (Monday) to (including) (i) consider and decide to approve the consolidated annual performance of the company and its subsidiaries for the year ending December 31, 2024, and its publication; (ii) consider the proposal for the payment of a final dividend (if any); and (iii) address any Other matters.
BIOSTAR PHARM-B: NOTICE OF BOARD MEETING
Beijing Biostar Pharmaceuticals to Join Hang Seng Composite Index
Huahaotian Medicine-B (02563) issued a profit warning, anticipating an annual net loss of between 0.146 billion yuan and approximately 0.151 billion yuan.
Huahao Zhongtian Pharmaceutical-B (02563) announced that the group expects to record a net loss ranging between...
BIOSTAR PHARM-B: PROFIT ALERT - EXPECTED REDUCTION IN LOSS
Huahao Zhongtian Pharmaceutical-B (02563) has been included in the Hang Seng Composite Index and is expected to become a symbol for the Hong Kong Stock Connect.
According to a Research Report from CITIC SEC, China Haotian Medicine-B (02563) is likely to be included in the Hong Kong Stock Connect, as it meets a series of standards including Market Cap, liquidity, and listing time.
